Filtered news list testing
List of Reports
.pdf
10/28/2022 - 2022 Half-year results (Presentation)
.pdf
10/20/2022 - Revenue on September 30, 2022
.pdf
10/07/2022 - Half-year financial report 2022
.pdf
09/26/2022 - Guerbet obtains one million euros of public funding from Bpifrance for a project developing AI for the early detection of pancreatic cancer
.pdf
09/21/2022 - Guerbet Announces U.S. Food And Drug Administration (FDA) Approval Of Eluciremtm
.pdf
09/21/2022 - 2022 Half Year Results
.pdf
07/21/2022 - H1 2022 Sales
.pdf
06/13/2022 - Guerbet receives EMA acceptance of Elucirem™ as the Brand Name for Gadopiclenol
Single report testing
.pdf
test report fabien V 09-07
Separator
Filtered images
Discover the latest news of Guerbet
Latest news
U.S. Food and Drug Administration (FDA) grants Breakthrough Device status to the Guerbet innovation: LIPIOJOINT
U.S. Food and Drug Administration (FDA) grants Breakthrough Device status to the Guerbet innovation: LIPIOJOINT
2024 revenue
2024 revenue
Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow®, innovative solution dedicated to oncology imaging
Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow®, innovative solution dedicated to oncology imaging